Posts by Mourabit Halima

A study published in NEJM on December 11, 2024, led by Komal L. Jhaveri and colleagues, evaluated Imlunestrant, a next-generation oral selective estrogen receptor (ER) degrader, in ER-positive, HER2-negative advanced…

Clinicians and researchers continue to seek targeted treatment strategies for EGFR-mutant non-small cell lung cancer (NSCLC), with an increasing number of clinical trials evaluating combination therapies. Two recent high-profile studies, the FLAURA-2 and MARIPOSA trials, have led to the FDA approval of new first-line treatment options for EGFR-mutant NSCLC in 2024.

Antibody-drug conjugates (ADCs) have emerged as a promising treatment modality for pancreaticobiliary cancers, offering targeted delivery of cytotoxic agents while minimizing systemic toxicity. Dr. Lei Zheng’s presentation at the ASCO…

From January 23 to 25, 2025, the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI 2025) was held in San Francisco, USA. At this prestigious event, Cadonilimab, the world's first bispecific antibody developed in China, achieved multiple breakthroughs in the treatment of gastrointestinal cancers.Several research teams, including Professors Jing Huang and Wang Qu from the Cancer Hospital Chinese Academy of Medical Sciences, Professor Rongbo Lin from Fujian Cancer Hospital, and Professor Wan He from Shenzhen People's Hospital, presented the latest research findings on Cadonilimab in the treatment of advanced esophageal squamous cell carcinoma (ESCC), mismatch repair-proficient/microsatellite-stable (pMMR/MSS) metastatic colorectal cancer (mCRC), and locally advanced rectal cancer (LARC). These studies demonstrated the potential of Cadonilimab-based combination therapies to enhance anti-tumor efficacy, prolong survival, and improve safety, laying the foundation for a new era of bispecific antibody therapy in gastrointestinal cancers.

The 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI 2025) successfully concluded on January 25. During the conference, numerous high-impact research findings were presented, including the ASPEN-06 study (Abstract #332), a global Phase II/III randomized trial evaluating the efficacy of evorpact (Evo) in combination with trastuzumab, ramucirumab, and paclitaxel (TRP) in patients with HER2-positive gastric and esophageal cancer who had previously received anti-HER2 therapy but experienced disease progression. At the conference, a reporter from Oncology Frontier had the opportunity to conduct an exclusive interview with Dr. Kohei Shitara from the National Cancer Center Hospital in Japan regarding this study. The following is a summary of the discussion.

The 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI 2025) has successfully concluded. At this prestigious event, Professor Yanhong Deng’s team from The Sixth Affiliated Hospital of…

The 2025 ASCO Gastrointestinal Cancers Symposium (ASCO GI) commenced in San Francisco on January 23, 2025. During the conference, Dr. Ying Yuan from The Second Affiliated Hospital of Zhejiang University School of Medicine presented the latest survival data and subgroup analysis from the BBCAPX study. Oncology Frontier had the privilege of discussing the updated findings with Dr. Ying Yuan. This article summarizes the key insights from the study to provide valuable updates for clinicians and researchers.